Tokyo Tape
Sign in
← Sakai Chemical Industry

Quarterly report · Q2

4078.TEDINET S100S5CT
Period2023-04-01 → 2023-09-30
Filed2023-11-08
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥40.5bn2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥83.9bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥42.7bn2022-04-01 → 2022-09-30Cons.Net sales
Operating income¥917m2023-04-01 → 2023-09-30Cons.Operating income
Operating income¥3.3bn2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income¥885m2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥4.6bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥3.8bn2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax¥773m2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥4.2bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)−¥2.0bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥2.3bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥2.9bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income−¥1.8bn2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥3.0bn2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥131.6bnat 2023-09-30Cons.Assets
Total assets¥128.0bnat 2023-03-31Cons.Assets
Total assets¥128.4bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥50.9bnat 2023-09-30Cons.Liabilities
Total liabilities¥43.3bnat 2023-03-31Cons.Liabilities
Net assets / equity¥80.7bnat 2023-09-30Cons.Net assets
Net assets / equity¥84.7bnat 2023-03-31Cons.Net assets
Net assets / equity¥85.8bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥15.6bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥12.4bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥15.5bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥12.2bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥11.7bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥10.5bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow¥3.2bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥773m2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥1.1bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥1.6bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥2.6bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.3bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥1.6bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥3.3bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.0bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-125.532023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-153.572023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥144.852022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥177.482022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥68.082022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio60.5%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio62.9%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio63.6%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥635m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥635m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥1.1bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue2023-04-01 → 2023-09-30¥36.8bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue external2023-04-01 → 2023-09-30¥36.3bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥498m
jpcrp040300-q2r_E00780-000Chemicalreportable segmentsegment profit2023-04-01 → 2023-09-30¥1.9bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue2023-04-01 → 2023-09-30¥4.3bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue external2023-04-01 → 2023-09-30¥4.2bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥136m
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentsegment profit2023-04-01 → 2023-09-30¥144m
—segment totalrevenue2023-04-01 → 2023-09-30¥41.1bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥40.5bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥635m
—segment totalsegment profit2023-04-01 → 2023-09-30¥2.0bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥860m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥860m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥1.1bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue2022-04-01 → 2022-09-30¥39.3bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue external2022-04-01 → 2022-09-30¥38.6bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥697m
jpcrp040300-q2r_E00780-000Chemicalreportable segmentsegment profit2022-04-01 → 2022-09-30¥4.2bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue2022-04-01 → 2022-09-30¥4.3bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue external2022-04-01 → 2022-09-30¥4.1bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥163m
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentsegment profit2022-04-01 → 2022-09-30¥240m
—segment totalrevenue2022-04-01 → 2022-09-30¥43.6bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥42.7bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥860m
—segment totalsegment profit2022-04-01 → 2022-09-30¥4.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 522
ItemContextValueUnit
Other clPrior1YearInstant5216000000JPY
Other clCurrentQuarterInstant6123000000JPY
Current liabilitiesPrior1YearInstant29237000000JPY
Current liabilitiesCurrentQuarterInstant31066000000JPY
Convertible bond type bonds with subscription rights to sharesPrior1YearInstant－JPY
Convertible bond type bonds with subscription rights to sharesCurrentQuarterInstant3000000000JPY
Long term loans payablePrior1YearInstant8467000000JPY
Long term loans payableCurrentQuarterInstant10463000000JPY
Provision for environmental measures nclPrior1YearInstant145000000JPY
Provision for environmental measures nclCurrentQuarterInstant138000000JPY
Net defined benefit liabilityPrior1YearInstant5071000000JPY
Net defined benefit liabilityCurrentQuarterInstant4982000000JPY
Deferred tax liabilitiesPrior1YearInstant139000000JPY
Deferred tax liabilitiesCurrentQuarterInstant1024000000JPY
Other nclPrior1YearInstant241000000JPY
Other nclCurrentQuarterInstant244000000JPY
Noncurrent liabilitiesPrior1YearInstant14066000000JPY
Noncurrent liabilitiesCurrentQuarterInstant19853000000JPY
LiabilitiesPrior1YearInstant43304000000JPY
LiabilitiesCurrentQuarterInstant50919000000JPY
Capital stockPrior1YearInstant21838000000JPY
Capital stockCurrentQuarterInstant21838000000JPY
Capital surplusPrior1YearInstant16293000000JPY
Capital surplusCurrentQuarterInstant16724000000JPY
Retained earningsPrior1YearInstant42482000000JPY
Retained earningsCurrentQuarterInstant39963000000JPY
Treasury stockPrior1YearInstant-1751000000JPY
Treasury stockCurrentQuarterInstant-1715000000JPY
Shareholders equityPrior1YearInstant78863000000JPY
Shareholders equityCurrentQuarterInstant76810000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant1254000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant2017000000JPY
Deferred gains or losses on hedgesPrior1YearInstant-0JPY
Deferred gains or losses on hedgesCurrentQuarterInstant3000000JPY
Foreign currency translation adjustmentPrior1YearInstant253000000JPY
Foreign currency translation adjustmentCurrentQuarterInstant671000000JPY
Remeasurements of defined benefit plansPrior1YearInstant117000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant109000000JPY
Valuation and translation adjustmentsPrior1YearInstant1624000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant2802000000JPY
Subscription rights to sharesPrior1YearInstant－JPY
Subscription rights to sharesCurrentQuarterInstant35000000JPY
Non controlling interestsPrior1YearInstant4229000000JPY
Non controlling interestsCurrentQuarterInstant1008000000JPY
Net assetsPrior1YearInstant84717000000JPY
Net assetsCurrentQuarterInstant80656000000JPY
Liabilities and net assetsPrior1YearInstant128021000000JPY
Liabilities and net assetsCurrentQuarterInstant131575000000JPY
Net salesPrior1YTDDuration42694000000JPY
Net salesCurrentYTDDuration40471000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass